Akèy › Karsinòm selil skuamèz tèt ak kou › Kentucky › Louisville
Etid klinik pou Karsinòm selil skuamèz tèt ak kou nan Louisville, KY
11 etid pou Karsinòm selil skuamèz tèt ak kou ap chèche patisipan nan sit nan ak bò kote Louisville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Ap rekriteFaz 2/3
- Site#0111, Louisville
- Site#0115, Louisville
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Norton Cancer Institute, Louisville
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Ap rekriteFaz 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 2
- Norton Cancer Institute, Louisville
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Ap rekriteFaz 2
- Baptist Health Floyd, New Albany · 4 mi lwen
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Ap rekriteFaz 3
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Ap rekriteFaz 1/2
- Norton Cancer Institute, Louisville
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Ap rekriteFaz 1/2
- Norton Cancer Institue Downtown, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Norton Cancer Institute /ID# 248903, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 115, Louisville
Etid Karsinòm selil skuamèz tèt ak kou nan lòt vil
- Houston, TX47 etid
- Los Angeles, CA42 etid
- Boston, MA40 etid
- Nashville, TN39 etid
- New York City, NY39 etid
- St. Louis, MO28 etid
- Arlington, VA26 etid
- Philadelphia, PA26 etid
- Chicago, IL26 etid
- Atlanta, GA24 etid
- San Antonio, TX22 etid
- Pittsburgh, PA22 etid
Lòt etid nan Louisville
- Kansè Poumon ki pa ti selil22 etid
- Obèsite17 etid
- Sipwa15 etid
- Kansè (tout kalite)14 etid
- Ensifizyans kadyak13 etid
- Leksemi mieloïd egi12 etid
- Myelom Miltip12 etid
- Kansè ovè12 etid
- Kansè nan tete11 etid
- Kansè poumon11 etid
- Melanom10 etid
- Kansè pwostat10 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.